Clinical Trial Protocol
Iranian Registry of Clinical Trials

07 Nov 2026

Therapeutic effect of curcumin in symptoms of mild to moderate Alzheimer's disease

Protocol summary

Summary

The purpose of this research is study of therapeutic effect of curcumin in clinical signs and quality of life in mild Alzheimer's disease.Trial is randomized , double blinded(for patients) and control with placebo.groups of study are mild to moderate Alzheimer's disease and patients that have psychic disorder become out of study. two groups of 35 patients for 12 weeks in addition to routine treatment , treat by curcumin capsule (500 mg twice a day) or placebo.Major indexes at the beginning and end of study are MMSE and quality of life questionnaires.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201507271165N11**
Registration date: **2015-09-24, 1394/07/02**
Registration timing: **registered_while_recruiting**

Last update:
Update count: **0**

Registration date

2015-09-24, 1394/07/02

Registrant information

Name

Yunes Panahi

Name of organization / entity

Baqiyatallah University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 8821 1524

Email address

yunespanahi@bmsu.ac.ir

Recruitment status

Recruitment complete

Funding source

Baghiyatallah University of Medical Sciences, Chemical Injeries Research Center

Expected recruitment start date

2015-08-23, 1394/06/01

Expected recruitment end date

2015-11-22, 1394/09/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Therapeutic effect of curcumin in symptoms of mild to moderate Alzheimer's disease

Public title

Effect of curcumin (tumeric) in Alzheimer's disease

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion Criteria : Sign informed consent ; mild Alzheimer; with out any of psychic disorder Exclusion Criteria : Discontinue of treatment more than 2 weeks ; disese becomes out of control ; allergic reaction to herbal compounds ,abnormal results in lab tests

Age

No age limit

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **70**

Randomization (investigator's opinion)

Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features
Randomized and double blinded and control with placebo(for patients)

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Baghiyatallah University of Medical Sciences
Street address
Mollasadra street,Vanak square
City
Tehran
Postal code
Approval date
2015-07-05, 1394/04/14
Ethics committee reference number
ir.bmsu.rec.1394.61

Health conditions studied

1

Description of health condition studied
Alzheimer's disease
ICD-10 code
G30.1
ICD-10 code description
Alzheimer disease with late onset

Primary outcomes

1

Description
Improvment of mental state
Timepoint
before and after of intervention (12 weeks)
Method of measurement
MMSE questionaire

2

Description
Improvment of quality of life
Timepoint
before and after of intervention (12 weeks)
Method of measurement
quality of life questionnaire

Secondary outcomes

1

Description
Interleukin18 (IL18)
Timepoint
befor and after of intervention(12 weeks)
Method of measurement
level of serum

2

Description
superoxide dismutase (SOD)
Timepoint
before and after of intervention(12 weeks)
Method of measurement
level of serum

3

Description
Glutathione peroxidase (GPO)
Timepoint
before and after of intervention(12 weeks)
Method of measurement
level of serum

4

Description
malondialdehyde(MDA)
Timepoint
befor and after of intervention(12 weeks)
Method of measurement
level of serum

Intervention groups

1

Description
intervention group: curcumin capsule, twice a day for 12 weeks
Category
Treatment - Drugs

2

Description
control group:placebo of curcumin, twice a day for 12 weeeks
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Baghiyatallah Hospital
Full name of responsible person
Dr Yunes Panahi
Street address
Mollasadra Street, Vanak Square
City
Tehran

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Vice Chancellor for Baghiyatallah University of Medical Sciences, Chemical Injeries Research Center
Full name of responsible person
Dr Yunes Panahi
Street address
Mollasadra Street, Vanak Square
City
Tehran
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Vice Chancellor for Baghiyatallah University of Medical Sciences, Chemical Injeries Research Center
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Pharmaceutical Sciences Branch Islamic Azad University
Full name of responsible person
Mahsa Bakhtiyari
Position
Pharm.D
Other areas of specialty/work
Street address
Yakhchal Street, Gholhak, Shariati Street
City
Tehran
Postal code
Phone
+98 21226400515
Fax
Email
publicrelation@iaups.ac.ir
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Baghiyatallah University of Medical Sciences, Chemical Injeries Research Center
Full name of responsible person
Dr Yunes Panahi
Position
Ph.D of Clinical Pharmacy
Other areas of specialty/work
Street address
Mollasadra Street, Vanak Square
City
Tehran
Postal code
Phone
+98 21 8821 1524
Fax
Email
yunespanahi@yahoo.com
Web page address

Person responsible for updating data

Contact

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty